Preliminary Studies on the Pharmacology of an Antidysrhythmic, Kö 1173, in Man

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 1973 Mar 1

PMID 4730880

Citations 7

Authors

M A Kiddie

R B Royds

T R Shaw

Affiliations

Soon will be listed here.

Citing Articles

The influence of urinary pH on the elimination of mexiletine.

Kiddie M, Kaye C, Turner P, Shaw T Br J Clin Pharmacol. 2012; 1(3):229-32.

PMID: 22454952 PMC: 1402565. DOI: 10.1111/j.1365-2125.1974.tb00241.x.

The renal excretion of mexiletine (Kö 1173) under controlled conditions of urine pH.

Kiddie M, Kaye C Br J Clin Pharmacol. 2012; 1(1):86-7.

PMID: 22454877 PMC: 1402406. DOI: 10.1111/j.1365-2125.1974.tb00214.x.

Clinical pharmacokinetics of mexiletine.

Labbe L, Turgeon J Clin Pharmacokinet. 1999; 37(5):361-84.

PMID: 10589372 DOI: 10.2165/00003088-199937050-00002.

Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.

Lledo P, Abrams S, Johnston A, Patel M, Pearson R, Turner P Eur J Clin Pharmacol. 1993; 44(1):63-7.

PMID: 8436157 DOI: 10.1007/BF00315282.

Clinical pharmacokinetics of the newer antiarrhythmic agents.

Gillis A, Kates R Clin Pharmacokinet. 1984; 9(5):375-403.

PMID: 6437721 DOI: 10.2165/00003088-198409050-00001.

References

Allen J, Ekue J, Shanks R, Zaidi S . The effect of Kö 1173, a new anticonvulsant agent on experimental cardiac arrhythmias. Br J Pharmacol. 1972; 45(4):561-73. PMC: 1665959. DOI: 10.1111/j.1476-5381.1972.tb08114.x. View